

CA

A Cancer Journal for Clinicians

Guidelines for Colonoscopy Surveillance after Cancer Resection: A Consensus Update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer

Douglas K. Rex, Charles J. Kahi, Bernard Levin, Robert A. Smith, John H. Bond, Durado Brooks, Randall W. Burt, Tim Byers, Robert H. Fletcher, Neil Hyman, David Johnson, Lynne Kirk, David A. Lieberman, Theodore R. Levin, Michael J. O'Brien, Clifford Simmang, Alan G. Thorson and Sidney J. Winawer
CA Cancer J Clin 2006;56;160-167

This information is current as of February 1, 2007

The online version of this article, along with updated information and services, is

To subscribe to the print issue of *CA: A Cancer Journal for Clinicians*, go to (US individuals only): <http://caonline.amcancersoc.org/subscriptions/>

CA: A Cancer Journal for Clinicians is published six times per year for the American Cancer Society by Lippincott Williams & Wilkins. A bimonthly publication, it has been published continuously since November 1950. *CA* is owned, published, and trademarked by the American Cancer Society, 1599 Clifton Road, NE, Atlanta, Georgia 30329. (©American Cancer Society, Inc.) All rights reserved. Print ISSN: 0007-9235. Online ISSN: 1542-4863.



located on the World Wide Web at:
<http://caonline.amcancersoc.org/cgi/content/full/56/3/160>

To subscribe to the print issue of *CA: A Cancer Journal for Clinicians*, go to (US individuals only): <http://caonline.amcancersoc.org/subscriptions/>

CA: A Cancer Journal for Clinicians is published six times per year for the American Cancer Society by Lippincott Williams & Wilkins. A bimonthly publication, it has been published continuously since November 1950. *CA* is owned, published, and trademarked by the American Cancer Society, 1599 Clifton Road, NE, Atlanta, Georgia 30329. (©American Cancer Society, Inc.) All rights reserved. Print ISSN: 0007-9235. Online ISSN: 1542-4863.



Dr. Rex is Chair, US Multi-Society Task Force on Colorectal Cancer; and Professor of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Dr. Kahi is Assistant Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN.

Dr. B. Levin is Vice President, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX.

Dr. Smith is Director, Cancer Screening, Cancer Control Science Department, American Cancer Society, Atlanta, GA.

Dr. Bond is Professor of Medicine, University of Minnesota; and Chief, Gastroenterology, Minneapolis VA Medical Center, Minneapolis, MN.

Dr. Brooks is Director, Prostate and Colorectal Cancer, Cancer Control Science Department, American Cancer Society, Atlanta, GA.

Dr. Burt is Interim Executive Director, Huntsman Cancer Institute and Professor of Medicine, University of Utah, Salt Lake City, UT.

Dr. Byers is Program Leader, Clinical Cancer Prevention and Control; and Professor, Department of Epidemiology, University of Colorado, Denver, CO.

Dr. Fletcher is Professor, Ambulatory Care and Prevention, Harvard Medical School, Boston, MA.

Dr. Hyman is Chief, General Surgery, University of Vermont, Burlington, VT.

Dr. Johnson is Professor of Medicine and Chief, Gastroenterology, Eastern Virginia School of Medicine, Norfolk, VA.

Dr. Kirk is Tim and Toni Hartman Professor, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Dr. Lieberman is Chief, Division of Gastroenterology, Oregon Health and Science University, Portland, OR.

(continued next page)

Guidelines for Colonoscopy Surveillance after Cancer Resection: A Consensus Update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer^{*,†}

Douglas K. Rex, MD; Charles J. Kahi, MD, MSc; Bernard Levin, MD; Robert A. Smith, PhD; John H. Bond, MD; Durado Brooks, MD, MPH; Randall W. Burt, MD; Tim Byers, MD, MPH; Robert H. Fletcher, MD, MSc; Neil Hyman, MD; David Johnson, MD; Lynne Kirk, MD; David A. Lieberman, MD; Theodore R. Levin, MD; Michael J. O'Brien, MD, MPH; Clifford Simmgang, MD; Alan G. Thorson, MD; Sidney J. Winawer, MD

ABSTRACT Patients with resected colorectal cancer are at risk for recurrent cancer and metachronous neoplasms in the colon. This joint update of guidelines by the American Cancer Society (ACS) and US Multi-Society Task Force on Colorectal Cancer addresses only the use of endoscopy in the surveillance of these patients. Patients with endoscopically resected Stage I colorectal cancer, surgically resected Stage II and III cancers, and Stage IV cancer resected for cure (isolated hepatic or pulmonary metastasis) are candidates for endoscopic surveillance. The colorectum should be carefully cleared of synchronous neoplasia in the perioperative period. In nonobstructed colons, colonoscopy should be performed preoperatively. In obstructed colons, double contrast barium enema or computed tomography colonography should be done preoperatively, and colonoscopy should be performed 3 to 6 months after surgery. These steps complete the process of clearing synchronous disease. After clearing for synchronous disease, another colonoscopy should be performed in 1 year to look for metachronous lesions. This recommendation is based on reports of a high incidence of apparently metachronous second cancers in the first 2 years after resection. If the examination at 1 year is normal, then the interval before the next subsequent examination should be 3 years. If that colonoscopy is normal, then the interval before the next subsequent examination should be 5 years. Shorter intervals may be indicated by associated adenoma findings (see Postpolypectomy Surveillance Guideline). Shorter intervals are also indicated if the patient's age, family history, or tumor testing indicate definite or probable hereditary nonpolyposis colorectal cancer. Patients undergoing low anterior resection of rectal cancer generally have higher rates of local cancer recurrence, compared with those with colon cancer. Although effectiveness is not proven, performance of endoscopic ultrasound or flexible sigmoidoscopy at 3- to 6-month intervals for the first 2 years after resection can be considered for the purpose of detecting a surgically curable recurrence of the original rectal cancer. (*CA Cancer J Clin* 2006;56:160-167.) © American Cancer Society, Inc., 2006.

*This article is being published jointly in *CA: A Cancer Journal for Clinicians* (online: May 30, 2006; print: May/June 2006) and *Gastroenterology* (print: May 2006) by the American Cancer Society and the American Gastroenterology Association.

†© 2006 American Cancer Society, Inc. and American Gastroenterology Association, Inc. Copying with attribution allowed for any noncommercial use of the work.

INTRODUCTION

Recommendations (Table 1) on the use of surveillance colonoscopy after resection of colorectal cancer were produced jointly by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society (ACS). They constitute the updated recommendations of both organizations. The rationale for combined guidelines by organizations is discussed in the accompanying joint recommendations on postpolypectomy surveillance. These guidelines were endorsed by the Colorectal Cancer Advisory Committee of the ACS and by the governing boards of the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy.

Table 2 summarizes the differences in these guidelines from previous guidelines on postcancer resection surveillance colonoscopy.

METHODOLOGY AND LITERATURE SEARCH

The literature search sought to identify randomized controlled trials and cohort studies in which patients with resected colorectal cancer and perioperative clearing of synchronous neo-

plasia by colonoscopy were followed to detect recurrent and/or metachronous neoplasms.

We searched the medical literature using MEDLINE (1966-January 17, 2005), the Cochrane Database of Systematic Reviews (fourth quarter 2004 update), and the Database of Abstracts of Reviews of Effects (fourth quarter 2004 update). In MEDLINE, subject headings for colorectal neoplasms were combined with subheadings and keywords for "surgery," "resection," "colonoscopy," "surveillance," and "follow-up" to identify relevant citations. Only studies published in the English language were included. Surveillance studies in patients with inflammatory bowel disease or hereditary nonpolyposis colorectal cancer (HNPCC) were specifically excluded. Keyword searches were also performed in the Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects to identify any additional systematic reviews. In addition, a manual search was performed using references from retrieved reports, review articles, guidelines, meta-analyses, editorials, and textbooks of gastroenterology.

Dr. T. R. Levin is Associate Chief, Gastroenterology, Kaiser Permanente Medical Center, Walnut Creek, CA.

Dr. O'Brien is Professor, Medical Pathology, Boston University School of Medicine, Boston, MA.

Dr. Simmang is Associate Professor of Surgery, Department of Colon and Rectal Surgery, University of Texas Southwestern Medical Center, Dallas, TX.

Dr. Thorson is Clinical Associate Professor of Surgery, Creighton School of Medicine and the University of Nebraska College of Medicine; Program Director, Section of Colon and Rectal Surgery, Creighton University, Omaha, NE.

Dr. Winawer is Paul Sherlock Chair in Medicine, Gastroenterology and Nutrition Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

This article is available online at <http://CAonline.AmCancerSoc.org>

TABLE 1 Postcancer Resection Surveillance Colonoscopy Recommendations

- 1. Patients with colon and rectal cancer should undergo high quality perioperative clearing.** In the case of nonobstructing tumors, this can be done by preoperative colonoscopy. In the case of obstructing colon cancers, computed tomography colonography with intravenous contrast or double contrast barium enema can be used to detect neoplasms in the proximal colon. In these cases, a colonoscopy to clear the colon of synchronous disease should be considered 3 to 6 months after the resection if no unresectable metastases are found during surgery. Alternatively, colonoscopy can be performed intraoperatively.
- 2. Patients undergoing curative resection for colon or rectal cancer should undergo a colonoscopy 1 year after the resection (or 1 year following the performance of the colonoscopy that was performed to clear the colon of synchronous disease).** This colonoscopy at 1 year is in addition to the perioperative colonoscopy for synchronous tumors.
- 3. If the examination performed at 1 year is normal, then the interval before the next subsequent examination should be 3 years.** If that colonoscopy is normal, then the interval before the next subsequent examination should be 5 years.
- 4. Following the examination at 1 year, the intervals before subsequent examinations may be shortened if there is evidence of hereditary nonpolyposis colorectal cancer or if adenoma findings warrant earlier colonoscopy.¹**
- 5. Periodic examination of the rectum for the purpose of identifying local recurrence, usually performed at 3- to 6-month intervals for the first 2 or 3 years, may be considered after low anterior resection of rectal cancer.** The techniques utilized are typically rigid proctoscopy, flexible proctoscopy, or rectal endoscopic ultrasound. These examinations are independent of the colonoscopic examinations described above for detection of metachronous disease.

TABLE 2 Differences between Current and Previous Guidelines on Postcancer Resection Surveillance Colonoscopy

In addition to careful perioperative clearing of the colorectum for synchronous lesions, a colonoscopy is recommended 1 year after surgical resection because of high yields of detecting early second, apparently metachronous cancers. Clinicians can consider periodic examination of the rectum for the purpose of identifying local recurrence after low anterior resection of rectal cancer.

We excluded articles if there was no evidence of perioperative colonoscopic clearing or if a modality other than colonoscopy (flexible sigmoidoscopy, barium enema) was used for perioperative clearing.

A total of 66 studies were retrieved for detailed evaluation, and 43 were excluded: 26 because of incomplete perioperative colonoscopic clearing or because this was accomplished with modalities other than colonoscopy, 13 did not pertain to the focus of our paper, three were reports of work in progress that were published in final form in other studies included in our analysis, and one reported the preliminary results of an ongoing trial. The remaining 23 studies were included in our analysis.²⁻²⁴

Evidence tables were created to summarize the studies and were circulated to members of the US Multi-Society Task Force and the ACS Colorectal Cancer Advisory Committee. The evidence was reviewed and recommendations developed at a joint meeting.

DISCUSSION OF EVIDENCE AND RATIONALE FOR THE RECOMMENDATIONS

Limitations in the Selected Studies

Some limitations were identified in interpreting the selected studies on postcancer surveillance colonoscopy literature.²⁻²⁴ For example, the term “metachronous cancer” had variable definitions. In some instances, it was based on the site of tumor appearance within the colon, and in others it was based on time after resection of the initial primary. Many studies made no mention of whether patients may have had hereditary nonpolyposis colorectal cancer. In some cohorts, there was incomplete follow up of patients. Surveillance intervals were different across studies. Some studies did not clearly separate metachronous tumors from anastomotic recurrences or anastomotic from local or regional recurrences. In some cases, there was also failure to report the stage of metachronous cancers and whether or not they were resectable for cure at the time they were diagnosed. In some studies, it was not clear whether colonoscopies were routine

procedures in asymptomatic surveillance patients versus diagnostic procedures based on symptoms or laboratory findings. Colonoscopy completion rates and complication rates were commonly not reported, and there was also frequently lack of information on mortality rates. Despite these limitations, a number of clinically relevant trends are evident regarding colorectal cancer recurrence, metachronous cancer, and the utility of surveillance procedures in patients with resected colorectal cancer.

Candidates for Postcancer Resection Surveillance Colonoscopy

In general, patients who undergo surgical resection of Stage I, II, or III colon and rectal cancers, or curative-intent resection of Stage IV cancers are candidates for surveillance colonoscopy. Patients who undergo curative endoscopic resection of Stage I colon cancers are also candidates for surveillance colonoscopy. Patients with Stage IV colon or rectal cancer that is unresectable for cure are generally not candidates for surveillance colonoscopy because their chance of survival from their primary cancer is low, and the risks of surveillance outweigh any potential benefit.

Goals of Surveillance: Detection of Recurrent Cancer versus Metachronous Cancers and Adenomas

There are two fundamental goals of surveillance of patients with resected colon or rectal cancer. One goal is the detection of early recurrences of the initial primary cancer at a stage that would allow curative treatment. The second goal is detection of metachronous colorectal neoplasms. In regard to detection of recurrences of the initial primary cancer, serial measurements of carcinoembryonic antigen are widely used.²⁵ In addition, recent meta-analyses of randomized controlled trials suggest that annual chest x-rays and computed tomography (CT) scans of the liver can improve survival from the original primary cancer by early detection of surgically curable recurrences.²⁶ The roles of serial performance of serum carcinoembryonic antigen measurements, serial chest x-rays,

and CT scans of the liver are not reviewed here. Neither individual randomized controlled trials of intensive surveillance with colonoscopy²⁰ nor meta-analyses of these trials²⁶ have demonstrated a survival benefit from the original primary tumor by performing colonoscopy at annual or shorter intervals. The failure of surveillance endoscopic exams to improve survival from recurrent colorectal cancer appears to result from relatively low rates of anastomotic or intraluminal recurrence and the observation that anastomotic or intraluminal recurrences are generally associated with intraabdominal or pelvic disease that is unresectable for cure.^{2-24,26,27} In summary, performance of annual colonoscopy for the purpose of detecting recurrent disease does not have an established survival benefit for patients with colorectal cancer. (However, as noted below, there is a rationale for surveillance of the rectum after resection of rectal cancer for the detection of local recurrence.) The primary goal of surveillance colonoscopy after resection of colorectal cancer is detection of metachronous neoplasms.

Distinguishing Rectal Cancer versus Colon Cancer Follow Up

Although there is no established benefit from endoscopic surveillance for the purpose of detecting early recurrences of the original cancer, in clinical practice many clinicians distinguish between rectal and colon cancer in this regard. The distinction is based on differences in the rates of local recurrence of rectal versus colon cancer. Specifically, in the case of colon cancer, recurrence at the anastomosis occurs in only 2% to 4% of patients.²⁻²⁴ Because the overwhelming majority of patients with endoscopically detected anastomotic recurrences in the colon are unresectable for cure, surveillance colonoscopy for this purpose generally should not be undertaken. On the other hand, local recurrence rates of rectal cancer can be 10 or more times higher.²⁸⁻³³

High recurrence rates of rectal cancer are partly a function of surgical technique and volume.²⁸⁻³³ Specifically, recurrence rates below 10% have been consistently reported when patients are operated on by a technique called total

mesorectal excision.³⁴⁻³⁶ This technique involves sharp dissection of the rectum and its surrounding adventitia along the first plane outside the adventitia (the mesorectal fascia).^{35,36} The technique can be performed using either an open or laparoscopic-assisted approach³⁷⁻⁴⁰ and has been reported to allow higher rates of successful low anterior resection⁴⁰ and lower rates of postoperative sexual dysfunction in men.⁴¹

Local recurrence rates of rectal cancer can also be reduced by administration of chemotherapy and radiation therapy,³⁴ which have been most effectively administered in the neoadjuvant (preoperative) setting to patients with locally advanced disease. Patients with rectal cancer typically undergo preoperative staging, either by endoscopic ultrasound⁴²⁻⁴⁴ or magnetic resonance imaging,⁴⁵⁻⁴⁸ followed by neoadjuvant chemoradiation in selected patients.⁴⁹ The combination of neoadjuvant chemoradiation and resection by surgeons trained in total mesorectal excision has resulted in very low recurrence rates for rectal cancer.³⁴ Because local recurrence rates for rectal cancer across the United States are generally higher than those achieved in series utilizing total mesorectal excision, there is a rationale for performing periodic examinations of the rectum by rigid or flexible proctoscopy or endoscopic ultrasound. These techniques have not been shown to improve survival, and the only rationale for their use is high rates of local recurrence.

When colon or rectal cancer is resected endoscopically and surgical resection is not planned because of favorable histology⁵⁰ and/or increased surgical risk, a follow-up endoscopic examination to inspect and biopsy the resection site is reasonable.⁵¹ The follow-up examination is considered standard in the case of a sessile malignant polyp removed by piecemeal resection.¹ These examinations are typically performed 3 to 6 months after the initial endoscopic resection.

Detection of Metachronous Neoplasms

A second potential benefit of surveillance colonoscopy is the detection of metachronous cancers at a surgically curable stage, as well as the prevention of metachronous cancers via

TABLE 3 Metachronous Cancers in Postcancer Resection Surveillance Colonoscopy Studies

Study	N	Colonoscopies	Metachronous CRCs (all)	Metachronous CRCs (within 24 months)	Dukes' A or B	Number Asymptomatic	Reoperation for Cure
Barillari ²	481		12	6*	9	6†	7
Barrier ³	61‡		0				
Carlsson ⁴	129	546	1	0	NS	NS	NS
Castells ⁵	199		0				
Chen ⁶	231		4	0	NS	4	4
Eckardt ⁷	212		0				
Granqvist ⁸	390	600	12	7	5§	6§	10
Green ⁹	3278		42	24	23	NS	NS
Juhl ¹⁰	133	316	4	0	4	4	4
Khoury ¹¹	389	3889	2	1	NS	NS	NS
Kjeldsen ¹²	597		10	NS	NS	8	8
Kronborg ¹³	239	710	4	3	4	NS	4
Makela ¹⁴	106		1	NS	NS	NS	1
McFarland ¹⁵	74	237	0				
Obrand ¹⁶	444		0				
Ohlsson ¹⁷	53¶		0				
Patchett ¹⁸	132		2	NS	NS	0	NS
Pietra ¹⁹	207		1	NS	NS	NS	NS
Schoemaker ²⁰	325	733	8	5	5	1	NS
Skaife ²¹	611	609**	5	1	NS	NS	NS
Stigliano ²²	322		5	0	NS	NS	NS
Togashi ²³	341	1570	22	9	17	NS	22
Weber ²⁴	75	197	2	1	2	NS	2
Total	9029	9407	137	57	69	29	62

*Paper states "more than one half" arose in first 24 months.

†Paper reports 46 combined local recurrences with metachronous tumors, of which 22 were asymptomatic; number calculated assumes similar proportion for metachronous cancers.

‡Subgroup who underwent perioperative colonoscopy.

§Paper reports 26 combined local recurrences with metachronous tumors, of which 10 were Dukes' A or B and 14 were asymptomatic; numbers calculated assume similar proportion for metachronous cancers.

¶Intensive surveillance subgroup (control group did not undergo routine colonoscopy).

**Two patients underwent barium enema for completion of incomplete colonoscopy.

identification and removal of adenomatous polyps. The incidence of metachronous cancers, the timing at which metachronous cancers occur, and the stage of these cancers at presentation or identification by surveillance colonoscopy should determine the optimal intervals for performance of surveillance colonoscopy directed toward metachronous disease. The evidence from published studies of postcancer resection surveillance in colonoscopy was reviewed to determine what these rates and timing of metachronous cancers are (Table 3). Limitations in interpretation of this literature were described above.

From 2% to 7% of patients with colorectal cancer have one or more synchronous cancers in the colon and rectum at the time of initial diagnosis.^{3,4,13,24,52,53} From a practical perspective, it is impossible to differentiate whether apparent metachronous cancers appearing in the interval

shortly after resection of colorectal cancer are true metachronous lesions or missed synchronous lesions. Provided that appropriate clearing of the colon is achieved in the perioperative period, all subsequently identified cancers are, for practical purposes, metachronous lesions.

Among 23 studies in which patients underwent perioperative clearing by colonoscopy, there were 9,029 patients in whom 137 apparent metachronous cancers developed.²⁻²⁴ Among studies in which the number of colonoscopies performed could be determined, 9,407 colonoscopies were performed to detect 60 metachronous cancers in 2,706 patients.^{4,8,10,11,13,15,20,21,23,24} This is a rate of 157 colonoscopies per metachronous cancer detected, which compares favorably to the rate of prevalent cancers detected during screening colonoscopy. Thus, among four screening colonoscopy studies in patients age 50 and old-

TABLE 4 Additional Recommendations Regarding Postcancer Resection Surveillance Colonoscopy

1. These recommendations assume that colonoscopy is complete to the cecum and that bowel preparation is adequate.
2. There is clear evidence that the quality of examinations is highly variable. A continuous quality improvement process is critical to the effective application of colonoscopy in colorectal cancer prevention.⁵⁰
3. Endoscopists should make clear recommendations to primary care physicians about when the next colonoscopy is indicated.
4. Performance of fecal occult blood test is discouraged in patients undergoing colonoscopic surveillance.
5. Discontinuation of surveillance colonoscopy should be considered in persons with advanced age or comorbidities (with less than 10 years of life expectancy), according to the clinician's judgment.
6. Surveillance guidelines are intended for asymptomatic people. New symptoms may need diagnostic workup.
7. Chromoendoscopy (dye-spraying) and magnification endoscopy are not established as essential to screening or surveillance.
8. Computed tomography colonography (virtual colonoscopy) is not established as a surveillance modality.

TABLE 5 Key Research Questions Regarding Surveillance of the Colorectum after Resection of Colorectal Cancer

1. What clinical, genetic, or biologic markers predict development of metachronous cancers (ie, stratify risk) in colorectal cancer patients without hereditary nonpolyposis colorectal cancer?
2. Are new colorectal cancers in the short-term interval after surgical resection true metachronous cancers or missed synchronous lesions?
3. Do follow-up procedures (flexible sigmoidoscopy, endoscopic ultrasound) after resection of rectal cancer improve any outcomes?
4. Should the treatment of rectal cancer (eg, neoadjuvant chemoradiation, total mesorectal excision) influence whether follow up for local recurrence is justified?
5. Should adjunctive testing (eg, immunochemical fecal occult blood testing) be added to colonoscopy in the surveillance of patients who have undergone resection of colorectal cancer?

er,⁵⁴⁻⁵⁷ the number of colonoscopies needed to detect one invasive cancer was 135. Excluding reference 55, which was performed in male veterans, (a group expected to have higher prevalence of neoplasia), 156 colonoscopies were performed per invasive cancer detected in the remaining three studies.^{54,56,57}

Among studies of post cancer resection surveillance colonoscopy, there were 57 metachronous cancers in the first 2 years after resection of the initial primary, with an incidence rate of 0.7% over this interval. This estimate is consistent with a review of tumor registries in Nebraska, which calculated an annual incidence for metachronous cancers of 0.35% per year.⁵⁸ When reported, 69 of 106 (65%) of metachronous cancers were Dukes' Stage A or B,^{2,8-10,13,20,23,24} 29 of 52 (56%) were asymptomatic,^{2,6,8,10,12,18,20} and 62 of 71 (87%) were operated for cure.^{2,6,8,10,12-14,23,24} Taken together, these findings were considered sufficient to warrant a colonoscopy 1 year after resection or after the perioperative clearing colonoscopy for the purpose of identification of apparently metachronous colorectal neoplasms. The recommendation to perform a colonoscopy at 1 year does not diminish the need for high quality in the performance of the perioperative clearing examination(s) for synchronous neoplasms.

Alternatives to Colonoscopy for Surveillance

Colonoscopy is considered the test of choice for detection of metachronous neoplasms in the postcancer resection surveillance colonoscopy setting (Table 4). Double contrast barium enema was less sensitive than colonoscopy for large and small polyp detection after resection of adenomas.⁵⁹

CT colonography has not been evaluated adequately in the surveillance setting, and results for polyp detection are quite mixed.⁶⁰⁻⁶³ Guaiac-based fecal occult blood testing has been generally considered to have very low positive predictive value after clearing colonoscopy. This was confirmed for the first 5 years after colonoscopy in a recent large study.⁶⁴ Immunochemical fecal occult blood testing warrants additional evaluation as an adjunct to colonoscopy⁶⁵ in this setting. Fecal DNA testing⁶⁶ has not been evaluated for postcancer resection surveillance and is not recommended for this indication.

KEY RESEARCH QUESTIONS

There are a number of questions that cannot be fully addressed by currently available evidence. Some of these key research questions are listed in Table 5.

REFERENCES

1. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. *CA Cancer J Clin* 2006;56:143–159.
2. Barillari P, Ramacciato G, Manetti G, et al. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. *Dis Colon Rectum* 1996;39:388–393.
3. Barrier A, Houry S, Huguier M. The appropriate use of colonoscopy in the curative management of colorectal cancer. *Int J Colorectal Dis* 1998;13:93–98.
4. Carlsson G, Petrelli NJ, Nava H, et al. The value of colonoscopic surveillance after curative resection for colorectal cancer or synchronous adenomatous polyps. *Arch Surg* 1987;122:1261–1263.
5. Castells A, Bessa X, Daniels M, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. *Dis Colon Rectum* 1998;41:714–723.
6. Chen F, Stuart M. Colonoscopic follow up of colorectal carcinoma. *Dis Colon Rectum* 1994;37:568–572.
7. Eckardt VF, Stamm H, Kanzler G, Bernhard G. Improved survival after colorectal cancer in patients complying with a postoperative endoscopic surveillance program. *Endoscopy* 1994;26:523–527.
8. Granqvist S, Karlsson T. Postoperative follow up of patients with colorectal carcinoma by colonoscopy. *Eur J Surg* 1992;158:307–312.
9. Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. *Ann Intern Med* 2002;136:261–269.
10. Juhl G, Larson GM, Mullins R, et al. Six-year results of annual colonoscopy after resection of colorectal cancer. *World J Surg* 1990;14:255–260.
11. Khoury DA, Opelka FG, Beck DE, et al. Colon surveillance after colorectal cancer surgery. *Dis Colon Rectum* 1996;39:252–256.
12. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow up after radical surgery for colorectal cancer. *Br J Surg* 1997;84:666–669.
13. Kronborg O, Hage E, Deichgraeber E. The remaining colon after radical surgery for colorectal cancer. The first 3 years of a prospective study. *Dis Colon Rectum* 1983;26:172–176.
14. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow up after radical surgery for colorectal cancer. Results of a prospective randomized trial. *Arch Surg* 1995;130:1062–1067.
15. McFarland RJ, Becciolini C, Lallemand RC. The value of colonoscopic surveillance following a diagnosis of colorectal cancer or adenomatous polyp. *Eur J Surg Oncol* 1991;17:514–518.
16. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. *Dis Colon Rectum* 1997;40:15–24.
17. Ohlsson B, Breland U, Ekberg H, et al. Follow up after curative surgery for colorectal carcinoma. Randomized comparison with no follow up. *Dis Colon Rectum* 1995;38:619–626.
18. Patchett SE, Mulcahy HE, O'Donoghue DP. Colonoscopic surveillance after curative resection for colorectal cancer. *Br J Surg* 1993;80:1330–1332.
19. Pietra N, Sarli L, Costi R, et al. Role of follow up in management of local recurrences of colorectal cancer: a prospective, randomized study. *Dis Colon Rectum* 1998;41:1127–1133.
20. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. *Gastroenterology* 1998;114:7–14.
21. Skaife P, Seow-Choen F, Eu KW, Tang CL. A novel indicator for surveillance colonoscopy following colorectal cancer resection. *Colorectal Dis* 2003;5:45–48.
22. Stigliano V, Fracasso P, Grassi A, et al. Endoscopic follow up in resected colorectal cancer patients. *J Exp Clin Cancer Res* 2000;19:145–148.
23. Togashi K, Konishi F, Ozawa A, et al. Predictive factors for detecting colorectal carcinomas in surveillance colonoscopy after colorectal cancer surgery. *Dis Colon Rectum* 2000;43:S47–S53.
24. Weber CA, Deveney KE, Pellegrini CA, Way LW. Routine colonoscopy in the management of colorectal carcinoma. *Am J Surg* 1986;152:87–92.
25. Benson AB 3rd, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. *J Clin Oncol* 2000;18:3586–3588.
26. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. *Cochrane Database Syst Rev* 2002:CD002200.
27. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. *BMJ* 2002;324:813.
28. Holm T, Johansson H, Cedermark B, et al. Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. *Br J Surg* 1997;84:657–663.
29. Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-related factors and outcome in rectal cancer. *Ann Surg* 1998;227:157–167.
30. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. *BMJ* 1991;302:1501–1505.
31. Steele RJ. The influence of surgeon case volume on outcome in site-specific cancer surgery. *Eur J Surg Oncol* 1996;22:211–213.
32. Harmon JW, Tang DG, Gordon TA, et al. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. *Ann Surg* 1999;230:404–411.
33. Panageas KS, Schrag D, Riedel E, et al. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. *Ann Intern Med* 2003;139:658–665.
34. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Dutch Colorectal Cancer G. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* 2001;345:638–646.
35. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg* 1982;69:613–616.
36. Cawthorn SJ, Parums DV, Gibbs NM, et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. *Lancet* 1990;335:1055–1059.
37. Fleshman JW, Wexner SD, Anvari M, et al. Laparoscopic vs. open abdominoperineal resection for cancer. *Dis Colon Rectum* 1999;42:930–939.
38. Kwok SP, Lau WY, Carey PD, et al. Prospective evaluation of laparoscopic-assisted large bowel excision for cancer. *Ann Surg* 1996;223:170–176.
39. Leung KL, Kwok SP, Lam SC, et al. Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. *Lancet* 2004;363:1187–1192.
40. Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Res Project. *Lancet* 2000;356:93–96.
41. Maurer CA, Z'Graggen K, Renzulli P, et al. Total mesorectal excision preserves male genital function compared with conventional rectal cancer surgery. *Br J Surg* 2001;88:1501–1505.
42. Fleshman JW, Myerson RJ, Fry RD, Kodner IJ. Accuracy of transrectal ultrasound in predicting pathologic stage of rectal cancer before and after preoperative radiation therapy. *Dis Colon Rectum* 1992;35:823–829.
43. Gualdi GF, Casciani E, Guadalajara A, et al. Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: comparison with histologic findings. *Dis Colon Rectum* 2000;43:338–345.
44. Hunerbein M, Pegios W, Rau B, et al. Prospective comparison of endorectal ultrasound, three-dimensional endorectal ultrasound, and endorectal MRI in the preoperative evaluation of rectal tumors. Preliminary results. *Surg Endosc* 2000;14:1005–1009.
45. Mathur P, Smith JJ, Ramsey C, et al. Comparison of CT and MRI in the preoperative stag-

- ing of rectal adenocarcinoma and prediction of circumferential resection margin involvement by MRI. *Colorectal Dis* 2003;5:396-401.
46. Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. *Colorectal Dis* 2003;5:392-395.
47. Radcliffe A, Brown G. Will MRI provide maps of lines of excision for rectal cancer? *Lancet* 2001;357:495-496.
48. Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. *Lancet* 2001;357:497-504.
49. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study, G. preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731-1740.
50. Rex D, Cummings O, Ulbright T. Coming to terms with pathologists over colon polyps with cancer or high-grade dysplasia. *J Clin Gastro* 2005;39:1-3.
51. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol* 2000;95:3053-3063.
52. Langevin JM, Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. *Am J Surg* 1984;147:330-333.
53. Pagana TJ, Ledesma EJ, Mittelman A, Nava HR. The use of colonoscopy in the study of synchronous colorectal neoplasms. *Cancer* 1984; 53:356-359.
54. Rex D, Sledge G, Harper P, et al. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. *Am J Gastroenterol* 1993;88: 825-831.
55. Lieberman D, Weiss D, Bond J, et al. 380. VACSG. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. *N Engl J Med* 2000;343:162-168.
56. Imperiale T, Wagner D, Lin C, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. *N Engl J Med* 2000;343:169-174.
57. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Colorectal Cancer Study, G. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. [see comment]. *N Engl J Med* 2004;351:2704-2714.
58. Cali RL, Pitsch RM, Thorson AG, et al. Cumulative incidence of metachronous colorectal cancer. *Dis Colon Rectum* 1993;36:388-393.
59. Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enemas for surveillance after polypectomy. National Polyp Study Work Group. *N Engl J Med* 2000;342:1766-1772.
60. Rockey D, Paulson E, Favis W, et al. Multicenter prospective comparison of colon imaging tests. *Gastroenterology* 2004;126:A2004.
61. Johnson CD, Harmsen WS, Wilson LA, et al. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. *Gastroenterology* 2003;125: 311-319.
62. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy). A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA* 2004;291:1713-1719.
63. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med* 2003;349:2191-2200.
64. Finkelstein S, Bini EJ. Annual fecal occult blood testing can be safely suspended for up to 5 years after a negative colonoscopy in asymptomatic average-risk patients. *Gastrointest Endosc* 2005;61:AB250.
65. Bampton PA, Sandford JJ, Cole SR, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. *Gut* 2005;54:803-806.
66. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med* 2004;351:2704-2714.